GE Healthcare’s FlexFactory to power DRL’s biosimilar expansion plans

ge-drl

FlexFactory will make DRL biopharmaceutical manufacturing set-up more flexible and efficient

GE Healthcare announced that Dr Reddy’s Laboratories (DRL) will install India’s first-ever FlexFactory, a single-use manufacturing platform to expand the biologics production capacity at its facility in Hyderabad. FlexFactory will make DRL biopharmaceutical manufacturing set-up more flexible and efficient, strengthening the company’s position in the global biosimilars market and allowing DRL to continue increasing patient access across the world for biotech-based therapies.

The new FlexFactory will help DRL increase its capacity to meet both the expected growth of its currently marketed biosimilars as well as support the launch of a significant portfolio of new biosimilar products in the years to come. With FlexFactory, DRL will be able to increase its manufacturing capacity swiftly as the overall project set-up timeline for FlexFactory is typically 9 to 12 months.

FlexFactory wil enable DRL transition from stainless steel to single-use technologies that bring enhanced flexibility and efficiency into their manufacturing set-up. Single-use technologies facilitate multi-product manufacturing and improve productivity by increasing the number of lots manufactured, as the change over time between products can be reduced by 50 per cent or more.

Please Wait while comments are loading...